SPY311.36-0.84 -0.27%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%

Natera Reports Medicare Admin. Contractor, Noridian, Issued Positive Coverage For Prospera Donor-Derived Cell-Free DNA Test

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, a Medicare Administrative Contractor (MAC), has issued positive coverage for the Prospera

Benzinga · 05/11/2020 18:42

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, a Medicare Administrative Contractor (MAC), has issued positive coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test. Noridian also announced it is developing a generic policy for dd-cfDNA testing that will include multiple commercially available tests under one consistent policy – Prospera's coverage will be under the new policy in the future along with others.

Natera, Inc. Logo (PRNewsFoto/Natera, Inc.)

Last week, Natera announced the early success of the ProActive study, which has already activated 18 of the top transplant centers and enrolled more than 145 patients. In addition, Natera announced strong interest in its early access program, receiving tests from 45% of the top 50, and 37% of the top 100 transplant centers by volume.

"We are very pleased with the overwhelmingly positive comments received from the transplant community during the Medicare open comment period, and to have received positive coverage for the Prospera test," said Phil Gauthier, M.D., a transplant nephrologist and Natera's medical director of transplant.